What 6 Analyst Ratings Have To Say About Abbott Laboratories Abbott Laboratories (NYSE:ABT) has observed the following analyst ratings within the last quarter: Benzinga · Jun 24, 2022
Here's How Much $1000 Invested In Abbott Laboratories 5 Years Ago Would Be Worth Today Abbott Laboratories (NYSE:ABT) has outperformed the market over the past 5 years by 7.3% on an annualized basis producing an average annual return of 17.14%. Currently, Abbott Laboratories has a market capitalization of $187.96 billion. Benzinga · Jun 24, 2022
This Top-Rated Healthcare Stock Is Trading at a 25% Discount Medical device company Abbott Laboratories (ABT) reported impressive first-quarter results and affirmed its strong performance guidance for fiscal 2022. Furthermore, the company is well-positioned to benefit from its diversified business. However, amid the heightened market volatility, the stock is trading 25.5% below its 52-week high. So, the current dip in… StockNews.com · Jun 24, 2022
FDA Probes Another Infant Death Given Abbott Formula, Less Than Month After Troubled Plant Reopens Problems for Abbott Laboratories' (NYSE: ABT) Sturgis plant in Michigan for baby formula powder refuse to subside. The FDA was recently notified of another infant's death who was given formula made at Abbott's Sturgis facility. Benzinga · Jun 23, 2022
FDA investigates death of another infant given Abbott formula U.S. Food and Drug Administration officials are investigating the death of another infant who was given formula made by Abbott Laboratories. Tribune News Service · Jun 22, 2022
Key US baby formula plant closes again as ‘torrential storms’ cause flooding Production halt at Abbott Laboratories in Michigan will probably extend shortages for ‘a few weeks’ The Guardian - US · Jun 16, 2022
More Trouble For Baby Formula Production As Thunderstorms, Flood, Hit Abbott's Troubled Michigan Plant Just a few weeks after reopening its baby formula Sturgis, Michigan plant, Abbott Laboratories (NYSE:ABT) said it paused EleCare specialty baby formula production after recent thunderstorms flooded part of the facility. The company has informed the FDA and will conduct comprehensive testing with an independent third party to ensure the plant is safe to… Benzinga · Jun 16, 2022
5 Hard-Hit Large-Cap Stocks Ready to Rebound The market turmoil this year, due to the sky-high inflation and the Fed’s hawkish tilt, has led several fundamentally solid large-cap stocks to trade below their intrinsic values. However, we believe quality large-cap stocks Broadcom (AVGO), Abbott (ABT), IQVIA (IQV), Agilent (A), and QUALCOMM (QCOM), which have declined significantly in… StockNews.com · Jun 10, 2022
If You Invested $1000 In This Stock 10 Years Ago, You Would Have $3,900 Today Abbott Laboratories (NYSE:ABT) has outperformed the market over the past 10 years by 2.54% on an annualized basis producing an average annual return of 14.5%. Currently, Abbott Laboratories has a market capitalization of $201.08 billion. Benzinga · Jun 8, 2022
Analyzing Abbott Laboratories's Short Interest Abbott Laboratories's (NYSE:ABT) short percent of float has risen 5.48% since its last report. The company recently reported that it has 13.46 million shares sold short, which is 0.77% of all regular shares that are available for trading. Benzinga · Jun 8, 2022
Abbott Laboratories vs. Edwards Lifesciences: Which Medical Device Stock is a Better Investment? The growing prevalence of chronic diseases, an increasing elderly population, and rapid adoption of advanced medical technologies are driving the growth of the medical device industry. The industry is expected to witness solid growth over the long term, to the benefit of the stocks of medical device companies Abbott (ABT)… StockNews.com · Jun 7, 2022
5 Analysts Have This to Say About Abbott Laboratories Over the past 3 months, 5 analysts have published their opinion on Abbott Laboratories (NYSE:ABT) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year. Benzinga · Jun 7, 2022
Abbott reopens baby formula plant in Michigan Abbott Laboratories said on Saturday that it has reopened its baby formula production plant in Sturgis, Michigan, taking a step toward alleviating an acute nationwide shortage that has sent parents scrambling for supplies. Reuters · Jun 4, 2022
Australian company to ship baby formula to shortage-hit US Joe Biden welcomes ‘good news’ as Bubs Australia increases production and reassures local customers The Guardian - AU · May 29, 2022
Benzinga · May 27, 2022 $100 Invested In Abbott Laboratories 10 Years Ago Would Be Worth This Much Abbott Laboratories (NYSE:ABT) has outperformed the market over the past 10 years by 2.65% on an annualized basis producing an average annual return of 14.68%. Currently, Abbott Laboratories has a market capitalization of $203.74 billion.
Benzinga · May 26, 2022 Lawmakers Seek Answers From FDA, Abbott On Nationwide Baby Formula Shortage FDA officials appeared before a congressional panel to answer questions about the crisis after Abbott Laboratories (NYSE: ABT) recalled some baby formula products and closed its manufacturing plant in Sturgis, Michigan.
The Guardian - UK · May 25, 2022 UK baby milk maker to fly formula to US to help ease shortages Lake District-based Kendamil steps in after largest producer in US had nationwide recall
The Independent UK · May 23, 2022 Mother sues baby formula producer Abbott for child’s premature death Suit claims Abbott Laboratories knew formula was risky for preterm infants
Salon · May 19, 2022 The baby formula scammers are here Parents are being exploited by unscrupulous individuals, often in online spaces
Benzinga · May 19, 2022 Abbott's Troubled Baby Formula Michigan Plant To Reopen In 1-2 Weeks: Reuters Abbott Laboratories (NYSE:ABT) and the FDA are reportedly on track to reopen the company's Sturgis, Michigan, baby formula manufacturing plant within one or two weeks, FDA Commissioner Robert Califf said. Abbott, the biggest U.S. supplier of powder infant formula, including Similac, agreed with the FDA on the steps needed to resume production at…
Tribune News Service · May 19, 2022 Viewpoint 3: To avoid the next infant formula crisis, make food safety a priority The Food and Drug Administration has reached an agreement with Abbott Laboratories to resume production at the company’s Sturgis, Michigan, facility. The announcement gives hope of relief for the three-fourths of American parents who rely on infant formula, and have struggled to find the product in recent weeks.
Benzinga · May 18, 2022 How Is The Market Feeling About Abbott Laboratories? Abbott Laboratories's (NYSE:ABT) short percent of float has risen 5.8% since its last report. The company recently reported that it has 12.79 million shares sold short, which is 0.73% of all regular shares that are available for trading.
Benzinga · May 18, 2022 US Lawmakers Reveal FDA Emergency Funds Bill To Tackle Baby Formula Shortage: Reuters U.S. House Democrats unveiled a bill to provide $28 million in emergency funds to the FDA to help it respond to a shortage of infant formula and strengthen supervision. A House Appropriations Committee said that the funds would provide the FDA with the resources to prevent fraudulent products from being placed on…
Benzinga · May 17, 2022 Where Abbott Laboratories Stands With Analysts Analysts have provided the following ratings for Abbott Laboratories (NYSE:ABT) within the last quarter:
Benzinga · May 17, 2022 US Baby Formula Crisis Could See Some Relief As FDA, Abbott Agree On Deal The baby formula shortage that has morphed into a crisis in the U.S. could soon see some relief following an agreement between market leader Abbott Laboratories (NYSE: ABT) and the Food and Drug Administration.